Tirzepatide versus other glucose-lowering therapies and risk of COPD exacerbations in patients with comorbid type 2 diabetes: a retrospective cohort study.
Tirzepatide just posted some strong numbers in a head-to-head matchup against other glucose-lowering therapies for people dealing with both type 2 diabetes (T2D) and chronic obstructive pulmonary disease (COPD). A new retrospective cohort study out of Taiwan looked at over 6,000 patients per group and compared tirzepatide to SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists.
Front Pharmacol
by Hsu WH, Chan YE, Wu JY et al.
“Tirzepatide versus other glucose-lowering therapies and risk of COPD exacerbations in patients with comorbid type 2 diabetes: a retrospective cohort study. Hsu WH(1), Chan YE(2), Wu JY(3)(4), Chuang YM(2), Kuo CY(2), Shiau BW(1), Huang PY(1), Lai CC(5)(6). Author information: (1)Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan. (2)Department of General Medicine, Chi Mei Medical Center, Tainan, Taiwan. (3)Department of Nutrition, Chi Mei Medical Center, Tainan, Taiwan. (4)Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan. (5)Department of Intensive Care Medicine, Chi Mei Medical Center, Tainan, Taiwan. (6)School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan. BACKGROUND: Chronic obstructive pulmonary disease (COPD) and type 2 diabetes (T2D) frequently coexist, sharing inflammatory and metabolic pathways. Tirzepatide (TZP), a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, has demonstrated metabolic and anti-inflammatory effects. However, its impact on pulmonary outcomes in patients with COPD and T2D remains uncertain. METHODS: Using the TriNetX global research network, we conducted a retrospective cohort study of adults with coexisting COPD and T2D prescribed TZP, sodium-glucose cotransporter-2 inhibitors (SGLT2i), dipeptidyl peptidase-4 inhibitors (DPP-4i), or glucagon-like peptide-1 receptor agonists (GLP-1RA). Propensity score matching (1:1) was performed separately for each comparison. Primary outcome was COPD exacerbation; secondary outcomes included all-cause mortality, acute respiratory failure, and lower respiratory tract infection. Outcomes were assessed during a prespecified observation period from day one through day 365 after the index date. RESULTS: Matched populations included 6,080 patients per group (TZP-SGLT2i), 4,684 (TZP-DPP-4i), and 6,727 (TZP-GLP-1RA). In the independently matched comparisons, median follow-up was 232 versus 365 days for TZP versus SGLT2i, 235 versus 365 days for TZP versus DPP-4i, and 233 versus 365 days for TZP versus other GLP-1RAs; incidence rates were expressed per 1,000 person-years. Compared with SGLT2i and DPP-4i, TZP significantly reduced COPD exacerbation risk (hazard ratio [HR] 0.73 [95% CI 0.64-0.82] and 0.72 [95% CI 0.63-0.82], respectively) and all-cause mortality (HR 0.30 [95% CI 0.23-0.38] and 0.24 [95% CI 0.18-0.31], respectively). TZP also reduced acute respiratory failure and lower respiratory tract infection risks. Outcomes were similar between TZP and GLP-1RA, except TZP showed lower mortality (HR 0.55 [95% CI 0.42-0.72]). CONCLUSION: Among patients with COPD and T2D, TZP use was associated with lower risks of COPD exacerbations, respiratory complications, and mortality compared with SGLT2i and DPP-4i, findings that warrant confirmation through randomized clinical trials. Copyright © 2026 Hsu, Chan, Wu, Chuang, Kuo, Shiau, Huang and Lai. PMCID: PMC13690786 Conflict of interest statement: The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.”
Here’s what stands out: tirzepatide users saw fewer COPD exacerbations and better survival rates than those on SGLT2i or DPP-4i. The stats don’t lie—risk of COPD flare-ups dropped by roughly 27% compared to both SGLT2 inhibitors and DPP-4 inhibitors. Mortality? Even more impressive, with hazard ratios down to 0.30 and 0.24. That’s not a small difference.
Compared to other GLP-1 receptor agonists, tirzepatide held its ground on most respiratory outcomes but still pulled ahead for overall mortality. The peptide also cut risk for acute respiratory failure and lower respiratory tract infections. Key takeaway: these results suggest a real advantage for tirzepatide in the metabolic-inflammation overlap seen in patients with both COPD and diabetes.
For researchers, this is a call to dig deeper. The study leans on real-world data, so the next step is randomized clinical trials to confirm what’s going on. But the signals are clear. Tirzepatide isn’t just hitting glucose targets—it’s showing promise for researchers interested in respiratory and inflammatory complications tied to T2D and COPD.
Get the details on tirzepatide or check our vendor directory if you’re sourcing research compounds. This peptide’s profile just got a lot more interesting.
Related Reading
[Application of cell-penetrating peptides in tumor therapy].
News · SmallReverse Micelles: The Gateway for Oral (Poly)Peptide Delivery.
News · Front BioinformEstablishing standardized evaluation protocols for peptide-target interaction prediction: the PTI-TAPE consensus framework eDelphi.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.